drugset / Trial / NCT00010400

Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome

NCT00010400

Completed 35 enrolled Johns Hopkins University
Non-randomizedTreatment

Summary

OBJECTIVES: I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide. II. Determine the toxicity of this drug in these patients.

Timeline

Start
1997-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg/kg Intravenous
Subject Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background filgrastim Protein / enzyme biologic